Inhibition of interleukin 1β induced rat and human cartilage degradation in vitro by the metalloproteinase inhibitor U27391

M P Seed, S Ismaiel, C Y Cheung, T A Thomson, C R Gardner, R M Atkins, C J Elson

Abstract
Interleukin 1 induced proteoglycan loss from cartilage in vitro was prevented by a biochemical inhibitor of metalloproteinase activity. The inhibitor also partially relieved the inhibition of proteoglycan synthesis caused by interleukin 1. The loss of glycosaminoglycan by rat and human femoral head cartilage in response to human recombinant interleukin 1β (rhIL-1β) was established, and the modulation of this loss by the metalloproteinase inhibitor U27391 was investigated. Rat femoral head cartilage consistently lost glycosaminoglycan in response to rhIL-1β whereas only a proportion (30%) of normal human femoral head cartilage did so. Concentrations of 10–100 μmol/l U27391 inhibited the action of rhIL-1β on rat femoral head cartilage, reversing both the loss of glycosaminoglycan and the inhibition of glycosaminoglycan synthesis. U27391 also prevented the reduction in glycosaminoglycan content of those human femoral head cartilage explants responsive to rhIL-1β. Metalloproteinase inhibition therefore prevents rhIL-1β induced glycosaminoglycan loss by rat and human femoral head cartilage, suggesting that inhibitors of such enzymes may prove to be of therapeutic benefit in erosive diseases in humans.

(Ann Rheum Dis 1993; 52: 37–43)

Osteoarthritis (OA) and rheumatoid arthritis (RA) cause substantial articular cartilage erosion and loss of matrix in the affected joints of patients, which can lead to a severe compromise of function. Fundamental experiments by Fell and Jubb identified the importance of synovial derived catabolic factor(s) which were capable of inducing cartilage damage in vitro, a constituent of which was later identified as interleukin 1 (IL-1). Interleukin 1 has since been implicated in the cartilage damage seen with OA and RA. It is synthesised by the diseased synovium in OA and RA and can be found in synovial fluids from patients with OA and RA. It is well established that recombinant human IL-1 (rhIL-1) can induce matrix loss, usually assessed as the loss of sulphated glycosaminoglycans, from the cartilage of several animal species in vitro8–11 and in vivo.12–14 Initial case reports using IL-1 harvested from cells illustrated that it was possible to induce degradation of human cartilage.15–16 It was not until later, however, that rhIL-1β was shown unambiguously to degrade normal articular cartilage and then only after prolonged (14 days) incubation with specimens from certain subjects.17

There is evidence that cartilage matrix degradation stimulated by IL-1 involves the action of metalloproteinases. For example, articular cartilage from pigs which is incubated with IL-1 releases proteoglycan fragments consistent with the action of one or more enzymes of this type. Interleukin 1 induces the release of metalloproteinases from human cartilage explants15–16 as well as from chondrocytes from various species,19–23 and these enzymes are capable of degrading cartilage matrix components.15–16 21 22 24 Campbell et al25 have shown since that proteoglycan fragments released by IL-1 stimulated human cartilage in situ have similar qualitative characteristics to those released by the isolated metalloproteinase in vitro.

Although it can be shown that classical metalloproteinase inhibitors such as EDTA, 1,10-phenanthroline, and ω1 macroglobulin will reduce the activity of this class of IL-1 inducible enzyme in isolation,20 26 27 direct evidence that the inhibition of these enzymes in situ will prevent the destructive action of IL-1 is sparse, if only due to non-specific actions of the agents on the chondrocyte28–30 or size exclusion from the cartilage. Several series of substrate inhibitors have been developed for an IL-1 inducible rabbit chondrocyte metalloproteinase, namely thiol, carboxyalkyl and hydroxamic acid peptides9 31 with the aim of developing agents which will alleviate cartilage dysfunction in arthritis disease.32 Of these, the hydroxamic acid peptides are the most potent and two have been reported to inhibit IL-1 induced proteoglycan loss from rabbit articular cartilage in vitro. Chemicals of this series are effective against the rabbit chondrocyte metalloproteinases collagenase and proteoglycanase which are induced by IL-1.32 Here we describe experiments which assessed the ability of a hydroxamic acid peptide, U27391, to modulate IL-1 induced proteoglycan loss and synthesis inhibition by rat femoral head articular cartilage and compared this with the same tissue obtained from humans.

Materials and methods
RAT FEMORAL HEAD CARTILAGE
Rat femoral head cartilage was incubated as described previously.11 Cartilage from 110–120 g male CFHB (Wistar strain, Interfauna) rats was dissected aseptically and washed serially. Optimum conditions were assessed by comparing RPMI 1640 containing 2–0 g/l glucose, 1 mM sodium pyruvate, 1 mM
glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, and 5% fetal calf serum, with Dulbecco's modified Eagle's medium (DMEM) containing 25 mM HEPES, 2.0 or 4.5 g/l glucose with 1 mM sodium pyruvate, 1 mM glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, and 5% fetal calf serum. Cartilage explants were preincubated for 48 hours at 37°C in a humidified atmosphere of 5% CO2/95% air in 2 ml medium on a rocker. The cartilages were then placed in fresh medium containing the drug vehicle and either U27391 (1–100 µmol/l) alone, rhIL-1β (100 ng/ml) alone, or rhIL-1β plus U27391 (1–100 µmol/l) for a further five days. Cartilage proteoglycan synthesis was assessed by the addition of sodium [35S]sulphate (0·46 kBq/ml) 16 hours before termination. Control cartilages were killed by freezing (–20°C) and thawing (54°C for 30 minutes) and incubated with sodium [35S]sulphate as for the living cartilage.

At termination the cartilages were removed and vortexed three times in 10 mM MgSO4 to remove inorganic [35S]sulphate. The cartilages were then weighed, and placed in 2 ml papain digestion buffer (20 mM disodium hydrogen orthophosphate, 1 mM EDTA, 2 mM dithiothreitol, and 0·25 mg/ml papain) and digested for three hours at 65°C.33 The media were diluted 1:2 in papain digestion buffer and digested as described earlier.

The degree of [35S]sulphate incorporation into glycosaminoglycans was assessed by the method of Jubb and Fell.34 A 50 µl volume of 10% cetylpyridinium chloride was added to 0·5 ml papain digest and incubated at 37°C for one hour. The samples were centrifuged at 13 000 g for 10 minutes and the supernatant aspirated. The glycosaminoglycan pellet was dissolved in 300 µl formic acid at 70°C for 10 minutes and added to 4 ml Optifluor with 0·5 ml papain buffer. The supernatants were also added, with 300 µl formic acid to ensure comparable quenching, to 4·0 ml Optifluor for liquid scintillation counting. The cartilage digests were then assessed for [35S]sulphate incorporation by liquid scintillation counting (0·5 ml digest : 5 ml Optifluor). Once the degree of [35S]sulphate incorporation into the glycosaminoglycan fraction had been determined, glycosaminoglycan synthesis in all further experiments was assessed by the content of [35S]sulphate in the cartilage digest.

The cartilage and medium were assessed for sulphated glycosaminoglycan content, assayed as chondroitin sulphate equivalents using the dimethyl methylene blue binding method33 modified for use on a microplate reader (Multi- scan MCC 340 MkII), and analysed using Titertek software (Flow Laboratories).

The loss of glycosaminoglycan from the cartilages was expressed as micrograms chondroitin sulphate equivalents released per milligram wet weight of cartilage (µg glycosaminoglycan/mg). Data were expressed as mean (SEM) and analysed by ANOVA with comparison of means (RS-1, BBN software).

HUMAN FEMORAL HEAD CARTILAGE

Macroscopically normal slices of human cartilage were obtained from the femoral heads of patients undergoing hemiarthroplasty following osteoporotic subcapital fracture of the femoral neck. Biopsy samples (3 × 3 mm) were taken from the human femoral head cartilage slices using a biopsy punch and each was cut in half. The two pieces were cultured and incubated as described in detail elsewhere.15 In brief, one half (control biopsy) was cultured in 2 ml RPMI 1640 containing 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin, 25 mM HEPES and 5% normal human AB serum. The other half (treated biopsy) was cultured in 2 ml RPMI 1640 containing either 10 ng/ml rhIL-1β alone or 10 ng/ml rhIL-1β plus U27391 (1–100 µmol/l). Each treatment was tested on 10 biopsy samples.

The cultures were incubated for 14 days at 37°C in a humidified atmosphere of CO2/air, and the media changed every two days. At the end of the culture period, the biopsy samples were blotted dry, weighed, and assayed for glycosaminoglycans using the technique described for rat femoral head cartilage. The glycosaminoglycan content of each half biopsy sample was expressed as micrograms glycosaminoglycan per milligram cartilage. The cartilage glycosaminoglycan content of each treated biopsy sample was compared with its paired untreated control using the Wilcoxon test. Owing to the zonal variation in the proteoglycan content of the human femoral head cartilage, the results were expressed as the percentage reduction in proteoglycan content induced by rhIL-1β, calculated as follows.

\[
\% \text{ reduction in cartilage glycosaminoglycan} = \frac{100 - \left( \text{glycosaminoglycan in treated biopsy/glycosaminoglycan in control biopsy} \right)}{100}
\]

MATERIALS

Recombinant human IL-1β produced by the expression of the carboxyterminal 153 amino acids of the 269 amino acid precursor in Escherichia coli and purified to homogeneity as assessed by sodium dodecylsulphate polyacrylamide gel electrophoresis was obtained from Roussel UCLAF, Paris. Its activity in the lymphocyte activation factor assay was 100 pg per unit and the endotoxin content was less than 1 ng/mg as determined by the Limulus assay. U27391 ((R,S)-N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-1 oxopentyl]-L-leucyl-L-phenyl alaninamide) was kindly supplied by Stuart Pharmaceuticals (ICI, Americas). Dulbecco's modified Eagle's medium, penicillin, streptomycin, sodium pyruvate, glutamine, and

![Figure 1: Structure of U27391 ((R,S)-N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-1 oxopentyl]-L-leucyl-L-phenyl alaninamide).](http://ard.bmj.com/Downloaded from group.bmj.com on December 18, 2017 - Published by group.bmj.com)
Inhibition of cartilage degradation by U27391

fetal calf serum were supplied by Gibco (Paisley, United Kingdom), and sodium $^{35}$S]sulphate by Amersham International. All other chemicals were supplied by Sigma (UK).

**Results**

INCORPORATION OF $^{35}$S]SULPHATE INTO RAT FEMORAL HEAD CARTILAGE GLYCOSAMINOGLYCAN

Twenty samples of rat femoral head cartilage incubated in DMEM supplemented with 4.5 g/l glucose for four days incorporated 3324.0 (379.9) cpm [S]sulphate. A total of 97.2 (0.6)% of the [S]sulphate was incorporated into precipitable glycosaminoglycan from living rat femoral head cartilage, indicating that most of the label was incorporated into glycosaminoglycan. Dead cartilage, after washing with 10 mM MgSO$_4$, contained 66.0 (12.0) cpm. For all subsequent experiments the [S]sulphate content of the rat femoral head cartilage papain digest was taken as an indication of glycosaminoglycan synthesis.

INCUBATION CONDITIONS FOR RAT FEMORAL HEAD CARTILAGE

A comparison was made between basal and rhIL-1β (100 ng/ml) stimulated rat femoral head cartilage cultured in either RPMI 1640 (2.0 g/l glucose) or DMEM (2.0 or 4.5 g/l glucose) to optimise the conditions required for [S]sulphate incorporation and glycosaminoglycan loss. Table 1 shows that [S]sulphate incorporation by unstimulated rat femoral head cartilage was highest when the rat femoral head cartilage was incubated in DMEM with 4.5 g/l glucose, especially when compared with 2.0 g/l glucose DMEM. Spontaneous glycosaminoglycan loss into the medium was also considerably higher from the latter samples. Incubation in RPMI 1640 gave a comparable spontaneous loss of glycosaminoglycan to 4.5 g/l glucose DMEM, though slightly and statistically significantly lower. Incubation with 100 ng/ml rhIL-1β showed that stimulated glycosaminoglycan release was highest (a 123% increase; p<0.001) in the presence of 4.5 g/l glucose DMEM, whereas that in the presence of RPMI 1640 was less significant (33.7%; p<0.05). This, coupled with the high incorporation of [S]sulphate in the 4.5 g/l glucose DMEM, led to the choice of this medium for subsequent experiments.

RECOMBINANT HUMAN INTERLEUKIN 1β INDUCED CARTILAGE DEGRADATION BY RAT FEMORAL HEAD CARTILAGE AND HUMAN FEMORAL HEAD CARTILAGE

Recombinant human interleukin 1β significantly increased glycosaminoglycan loss from rat

<table>
<thead>
<tr>
<th>Glycosaminoglycan loss (μg/mg)</th>
<th>[S]Sulphate (cpm)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Basal</strong></td>
<td><strong>[S]Sulphate (cpm)</strong></td>
</tr>
<tr>
<td>RPMI 1640 (2.0 g/l glucose)</td>
<td>3.18 (0.19)***</td>
</tr>
<tr>
<td>DMEM (2.0 g/l glucose)</td>
<td>5.53 (0.32)**</td>
</tr>
<tr>
<td>DMEM (4.5 g/l glucose)</td>
<td>3.87 (0.13)**</td>
</tr>
</tbody>
</table>

DMEM = Dulbecco’s modified Eagle’s medium; rhIL-1β = recombinant human interleukin 1β.

*p<0.05; **p<0.01; ***p<0.001 (n=10) when compared with 4.5 g/l glucose DMEM.

Figure 2  Induction of (A) glycosaminoglycan loss (μg glycosaminoglycan/mg cartilage) and (B) inhibition of [S]sulphate uptake (cpm per cartilage) by rat femoral head cartilage explants cultured with recombinant human interleukin 1β (rhIL-1β) (mean (SEM); n=10). Cartilages killed by freeze thawing contained 765.8 (85) cpm [S]sulphate.
femoral head cartilage into the medium from 5.71 (0.22) μg/mg to a maximum of 9.91 (0.58) μg/mg (n=10; p<0.001) at 100 ng/ml (EC₅₀ 13.1(2-2) ng/ml; n=6) and concomitantly inhibited [³⁵S]sulphate incorporation by cartilage from 4855.8(178.8) to 2170.3(210.4) cpm (n=10; p<0.001) at 100 ng/ml (EC₅₀ 12.0 (1-6) ng/ml; n=6). There was no evidence of a preferential sensitivity of either glycosaminoglycan loss or [³⁵S]sulphate uptake to the action of rhIL-1β (fig 2) at five days of incubation. As 100 ng/ml rhIL-1β gave the greatest effect, this concentration was used when assessing the actions of U27391.

Recombinant human interleukin 1β at 10 ng/ml also stimulated human femoral head cartilage explants to lose glycosaminoglycan over 14 days. The reduction, compared with explants cultured with medium alone, was 18.6(2.6%) (n=10; p<0.005), 11.0(2.5%) (n=10; p<0.003), and 21.0(3.1%) (n=10; p<0.001) for cartilage from three subjects. In contrast, specimens from six other subjects showed no significant reduction in glycosaminoglycan content ranging from 1 to 8% loss (n=10). As 10 ng/ml rhIL-1β gave an appreciable loss of glycosaminoglycan from human femoral head cartilage, this concentration was used when assessing the action of U27391.

### MODULATION OF RAT FEMORAL HEAD CARTILAGE GLYCOSAMINOGLYCAN LOSS AND SYNTHESIS BY U27391

The action of U27391 on the basal unstimulated release of glycosaminoglycan into the incubation medium was investigated. Figure 3 illustrates that at concentrations of 30 μmol/l and above, U27391 inhibited resting glycosaminoglycan release from 4.28(0-10) to 2.90(0.13) μg/mg at 30 μmol/l (p<0.01; n=10) and 3.04(0.17) μg/mg at 100 μmol/l (p<0.05; n=10). U27391 had no consistent action on [³⁵S]sulphate incorporation except for a statistically significant reduction in [³⁵S]sulphate incorporation at 1 μmol/l (p<0.01; n=10).

### MODULATION OF RECOMBINANT HUMAN INTERLEUKIN 1β INDUCED RAT FEMORAL HEAD CARTILAGE GLYCOSAMINOGLYCAN LOSS AND SYNTHESIS BY U27391

Co-incubation of rat femoral head cartilage with U27391 resulted in a highly significant reduction in rhIL-1β stimulated glycosaminoglycan release from 9.7(0.59) to 5.24(0.42) μg/mg (n=10; p<0.001) at 10 μmol/l, see fig 4A), and also reduced glycosaminoglycan loss to below basal levels at the highest concentration from 4.28(0-10) to 3.48(0.12) μg/mg (100 μmol/l; p<0.05; n=10). The rhIL-1β induced suppression of glycosaminoglycan synthesis remained unaffected by U27391 at 10 μmol/l (basal 6070.2(188.8); 100 ng/ml rhIL-1β 2873.8(338.3); 10 μmol/l U27391 2807.8(213.5) cpm) but was significantly reversed at 100 μmol/l to 4460 (286.2) cpm (n=10; p<0.01; see fig 4B). As with the unstimulated cartilage, U27391 at 1 μmol/l again significantly reduced [³⁵S]sulphate incorporation from 2873.8(338.3) to 1535.7 (317.5) cpm (p<0.01; n=10).

---

**Figure 3** Effect of U27391 (1–100 μmol/l) on the basal (A) glycosaminoglycan release and (B) [³⁵S]sulphate incorporation by rat femoral head cartilage in culture (mean (SEM)). *p<0.01; **p<0.05; n=10. Cartilages killed by freeze thawing contained 67.7(8.7) cpm [³⁵S]sulphate.
Inhibition of cartilage loss from human interleukin 1β (U27391) (100 ng/ml) induced A) glycosaminoglycan loss and B) inhibition of [35S]sulphate incorporation by rat femoral head cartilage in culture (mean (SEM), **p<0.01; ***p<0.001; n=10) by U27391. Closed symbols indicate basal controls without rhIL-1β. Cartilages killed by freeze thawing contained 677-787 cpm [35S]sulphate.

U27391 in the presence of 10 ng/ml rhIL-1β and fig 5 shows that these explants lost significantly less glycosaminoglycan than those incubated with rhIL-1β alone. The loss of glycosaminoglycan content from 10 biopsy samples was reduced from 18-6(2-6)% to 10-4(2-5) (p<0.01), 5-6(4-1) (p<0.01) and 5-9(2-6)% (p<0.01) at 10, 50 and 100 μmol/l U27391 respectively. Similar results were obtained with explants from another cartilage, responsive to rhIL-1β from a patient with osteoarthritis. The percentage loss of glycosaminoglycan compared with control biopsy samples incubated with rhIL-1β was 12-6(3-0), and 8-9(4-3), 12-2(3-1) and 4-3(6-6) for explants incubated with rhIL-1β in the presence of 10, 50, and 100 μmol/l U27391 respectively. The significance was affected by the variable glycosaminoglycan content between the biopsy samples, a characteristic of this disease.

Discussion

The results reported in this paper compare the response of rat and human femoral articular cartilage to rhIL-1β and its reduction by a metalloproteinase inhibitor. Although there is considerable evidence for the degradation of animal cartilage in response to IL-1, there is less evidence for human cartilage responding to IL-1 in a similar fashion. For example, Campbell et al claim to be the first to show glycosaminoglycan release from human cartilage explants, though the number of times this result was obtained is unclear. Similarly Shinmei et al reported briefly that IL-1 stimulated glycosaminoglycan loss from human cartilage slices as judged by the reduction in staining with toluidine blue. The source and purity of the IL-1 used was not given, however. Although this paucity of information could be due to differences in the incubation requirements of human cartilage described here and elsewhere, it has also become apparent, as is confirmed here, that there may be two populations of human cartilage which differ in their ability to respond to IL-1, with only about a third being responsive to degradation. Probably for this...
reason investigations into the actions of IL-1 on human cartilage have been impeded. We have tested several samples of human femoral head cartilage for their reactivity to rhIL-1β and investigated the inhibition of metalloproteinase using the synthetic inhibitor U27391. By necessity, direct comparisons with rat femoral head cartilage using identical incubation conditions cannot be made, as under the optimum conditions and short five day time course described here for rat femoral head cartilage, human femoral head cartilage does not respond to rhIL-1β with a reduction in glycosaminoglycan content. Conversely, we have found that rat femoral head cartilage incubated under conditions favourable for human femoral head cartilage does not respond optimally (data not shown). Differences in the sampling of the tissues have also necessitated the use of different methods for expressing glycosaminoglycan loss, as the glycosaminoglycan content of human femoral head cartilage varies according to the site of biopsy, and thus comparison must be made with paired biopsy samples taken from the same area. This technique cannot be applied to rat femoral head cartilage as the division of the femoral head cartilage into two results in substantial and sustained glycosaminoglycan loss. The glycosaminoglycan release into the supernatants for human cartilage explants is <10 μg/ml, which is less than the limit of detection of the glycosaminoglycan assay. The most likely explanation for this finding is that as the glycosaminoglycan content of the explants averages about 150 μg (4.5 mg at 33 μg glycosaminoglycan/mg mass) and only 20% was lost, then at most only 30 μg will be released over the 14 day incubation period. As the medium was collected every two days, it would contain less than 5 μg/ml on average.

The main finding reported here is that rat femoral head cartilage responds to IL-1 with a dose dependent loss of proteoglycan into the incubation medium coupled with a reduction in [35S]sulphate uptake and thus proteoglycan synthesis. Likewise the human femoral head cartilage samples chosen for this study responded with a reduction in proteoglycan content. Rat femoral head cartilage in general appears to be less sensitive to rhIL-1β than human femoral head cartilage, probably as a result of the species difference, which necessitated the use of 100 ng/ml rhIL-1β as opposed to 10 ng/ml in human femoral head cartilage when assessing the effect of U27391. In the two instances, incubation with U27391 resulted in the inhibition of proteoglycan loss. Previously, attempts to inhibit IL-1 induced proteoglycan loss from living cartilage by various biochemical inhibitors of metalloproteinases have met with little success, with the exception of three examples of the hydroxamic acid series, U24522 and U24278 and Ro31-4724. Although it could be argued that these agents are acting through non-specific actions on cartilage, as found with chloroquine, 1,10-phenanthroline, and AFMA, for example, they do not inhibit cartilage viability at active concentrations. We also observed no significant changes in sulphate incorporation at concentrations between 3 and 100 μmol/l, but with an atypical reduction in sulphate incorporation at 1 μmol/l U27391. This remains unexplained; however, this effect did occur in more than one experiment and was not reflected in changes in glycosaminoglycan loss. Typically, we have found that significant and dose related changes in either protein synthesis or sulphate incorporation are required before a reduction in rhIL-1β stimulated glycosaminoglycan loss is seen, which is not the case here. More importantly the opposite occurred, and the rhIL-1β induced reduction in [35S]sulphate incorporation by rat femoral head cartilage was substantially attenuated by treatment with U27391. This could indicate, but does not prove, that the inhibition of metalloproteinase activity may not only prevent proteoglycan degradation induced by IL-1, but also allows a recovery of proteoglycan synthesis or its retention within the cartilage, in a manner true to the concept of 'chondroprotection'.

Although showing that the inhibition of cartilage degradation by reducing metalloproteinase activity in human cartilage is a promising approach to the problem of cartilage degradation in disease, the data presented here conversely illustrate the importance of metalloproteinases in rhIL-1β induced proteoglycan loss. U27391 is active against the proteoglycanase and collagenase released by IL-1 stimulated chondrocytes, but is tenfold more active against the former (IC50 4.2×10^-8 and 4.1×10^-7 mol/1 respectively). Other as yet uncharacterised mechanisms of cartilage degradation are being revealed, however. Studies of the proteoglycan fragments released from stimulated cartilage in vitro have identified the initial sites of cleavage to be between the G1 and G2 globular domains of the proteoglycan core protein, . Interestingly, a major site of cleavage on the core protein uncharacteristic of that produced by stromelysin has been identified. The involvement of cysteiny1 proteases has also been shown in the degradation of discs of bovine nasal septum with the use of the lipophilic cysteiny1 protease inhibitor EP475. Other inhibitors without lipophilicity were found to be inactive, indicating either intracellular compartmentalisation of the enzymes or their release into other loci requiring membrane penetration. It is unknown if these mechanisms are important in the initial processes for the cleavage of the proteoglycan core protein as fragments characteristic of cysteiny1 proteinase activity are not found. Despite these possibilities, metalloproteinase inhibition with U27391 remains effective, and could reflect the relatively uncharacterised nature of the enzymes against which it was developed. Although U27391 reduced rhIL-1β stimulated and unstimulated proteoglycan loss to less than basal levels to a similar degree, it remains to be shown at which position the remaining core proteins are cleaved to determine the residual mechanisms under these conditions. In the absence of effective protection against cartilage erosion in RA and OA, it is promising to note that an agent developed as an inhibitor...
of rabbit metalloproteinase in in vitro animal systems is effective using human cartilage. We conclude that the inhibition of metalloproteinase activity is an effective method of reducing rheumatoid-induced proteolytic resorption of cartilage.

There is an indication that this inhibitionmay also result in more efficient proteoglycan retention or synthesis by cartilage under conditions of synthesis inhibition and requires further investigation.

We thank Sturt Pharmaceuticals (ICI Americas) for the kind donation of U27391.


Inhibition of interleukin 1 beta induced rat and human cartilage degradation in vitro by the metalloproteinase inhibitor U27391.

M P Seed, S Ismaiel, C Y Cheung, T A Thomson, C R Gardner, R M Atkins and C J Elson

Ann Rheum Dis 1993 52: 37-43
doi: 10.1136/ard.52.1.37

Updated information and services can be found at:
http://ard.bmj.com/content/52/1/37

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/